<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.0//EN" "http://www.ncbi.nlm.nih.gov:80/entrez/query/static/PubMed.dtd">
<ArticleSet>
	<Article>
		<Journal>
			<PublisherName/>
			<JournalTitle>IJOTM</JournalTitle>
			<Issn>2008-6490</Issn>
			<Volume>7</Volume>
			<Issue>3</Issue>
			<PubDate PubStatus="epublish">
				<Year>2016</Year>
				<Month>07</Month>
				<Day>1</Day>
			</PubDate>
		</Journal>
		<ArticleTitle>Tacrolimus Dose Requirement in Iranian Kidney Transplant Recipients within the First Three Weeks after Transplantation</ArticleTitle>
		<FirstPage>167</FirstPage>
		<LastPage>171</LastPage>
		<Language>EN</Language>
		<AuthorList>
			<Author>
				<FirstName>S</FirstName>
				<LastName>Dashti-Khavidaki</LastName>
				<Affiliation>Nephrology Research Center, Tehran University of Medical Sciences, Tehran, Iran. dashtis@sina.tums.ac.ir</Affiliation>
			</Author>
			<Author>
				<FirstName>S</FirstName>
				<LastName>Ghaffari</LastName>
			</Author>
			<Author>
				<FirstName>M</FirstName>
				<LastName>Gohari</LastName>
			</Author>
			<Author>
				<FirstName>MR</FirstName>
				<LastName>Khatami</LastName>
			</Author>
			<Author>
				<FirstName>Z</FirstName>
				<LastName>Zahiri</LastName>
			</Author>
		</AuthorList>
		<History>
			<PubDate PubStatus="received">
				<Year>2015</Year>
				<Month>02</Month>
				<Day>16</Day>
			</PubDate>
		</History>
		<Abstract>Background: Tacrolimus is the main immunosuppressive agent in many kidney transplant protocols with an initial recommended daily dose of 0.2 mg/kg of ideal body weight (IBW). However, due to the high inter- and intra-patient variability in its pharmacokinetics, the required tacrolimus doses may differ markedly from patient to patient.Objective: To assess the required tacrolimus dose to achieve the desired whole blood concentration within the first three weeks after kidney transplantation among Iranian patients.Methods: This cross-sectional study was performed at kidney transplantation ward of Imam Khomeini Hospital Complex where almost all patients receive thymoglobulin induction therapy and a calcineurin inhibitor, mainly tacrolimus, plus mycophenolate, and prednisolone as maintenance immnosuppressive drugs with the target tacrolimus whole blood concentration of 8&amp;ndash;12 ng/mL for the first month after transplantation.Results: The mean&amp;plusmn;SD administered daily dose of tacrolimus during the first three weeks after transplantation was 0.085&amp;plusmn;0.024 mg/kg of IBW that resulted in a mean&amp;plusmn;SD whole blood concentration of 10.34&amp;plusmn;5.44 ng/mL. The required mean&amp;plusmn;SD dose of the drug to achieve the desired whole blood level of 8&amp;ndash;10 ng/mL was 0.08&amp;plusmn;0.02 mg/kg. Only 27.4% of the assessed tacrolimus blood levels were within the desired range. Compared with males, females needed 19% more daily dose of tacrolimus to reach similar whole blood levels. Tacrolimus blood levels were significantly correlated with daily tacrolimus doses (r=0.307, p=0.001) and patients&amp;rsquo; age (r=0.283, p=0.003).Conclusion: It seems that Iranian kidney transplant recipients need lower daily doses of tacrolimus to achieve the desired whole blood levels; compared with males, females need a higher dose.</Abstract>
	</Article>
</ArticleSet>
